| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
7beta-Hydroxylathyrol targets various signaling pathways involved in inflammation and cancer. As a lathyrane-type diterpenoid, it may inhibit the activation of NF-κB and reduce the expression of pro-inflammatory cytokines. The compound may also induce apoptosis in cancer cells through the mitochondrial pathway and inhibit cell proliferation. The compound's multiple hydroxyl groups may contribute to its antioxidant activity by scavenging free radicals and reducing oxidative stress. The compound may modulate the PI3K/Akt and MAPK signaling pathways. The compound's mechanism of action is likely related to its ability to interact with cellular membranes and modulate signal transduction pathways.
|
|---|---|
| ln Vitro |
In vitro, 7beta-Hydroxylathyrol has been shown to inhibit the growth of various cancer cell lines and induce apoptosis. The compound's anti-proliferative effects are likely mediated through the induction of cell cycle arrest and apoptosis. The compound may also have anti-inflammatory effects by reducing the production of pro-inflammatory cytokines and inhibiting the activation of NF-κB. The compound's antioxidant activity may contribute to its cytoprotective effects. The compound's effects on cell viability, apoptosis, and inflammatory marker expression can be assessed in various cell culture systems.
|
| ln Vivo |
In vivo, 7beta-Hydroxylathyrol has been studied in animal models of inflammation and cancer. The compound may have anti-tumor effects in xenograft models and anti-inflammatory effects in models of inflammation. Its pharmacokinetics and bioavailability are areas of active research. The compound's efficacy depends on the dose, route of administration, and the specific disease model. Further in vivo studies are needed to fully characterize the compound's therapeutic potential and safety profile.
|
| Enzyme Assay |
For non-cellular enzyme assays, 7beta-Hydroxylathyrol can be tested for inhibition of enzymes such as COX-2, iNOS, and MMPs using standard enzyme activity assays. The compound's antioxidant activity can be evaluated using cell-free assays such as DPPH, ABTS, or FRAP radical scavenging assays. The compound's ability to modulate NF-κB activity can be assessed using electrophoretic mobility shift assays (EMSA) or luciferase reporter assays with purified components.
|
| Cell Assay |
For in vitro cell-based assays, cancer cell lines and inflammatory cell models are cultured and treated with 7beta-Hydroxylathyrol. Cell proliferation is assessed using MTT or CCK-8 assays. Apoptosis is evaluated by flow cytometry using Annexin V/PI staining or by assessing caspase activity. Inflammatory marker expression is measured by ELISA or Western blotting. Signaling pathway activation is assessed using phospho-specific antibodies. The compound's effects on cell cycle progression can be analyzed using flow cytometry.
|
| Animal Protocol |
For in vivo animal studies, 7beta-Hydroxylathyrol can be administered to animal models of disease. Inflammation models (such as carrageenan-induced paw edema or DSS-induced colitis) and cancer models (such as xenograft) can be used. Inflammatory markers, tumor growth, and survival are assessed. Pharmacokinetic and pharmacodynamic studies can be performed to characterize the compound's absorption, distribution, metabolism, and excretion.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of 7beta-Hydroxylathyrol include a molecular weight of 350.45 and a molecular formula of C₂₀H₃₀O₅. The compound is a white to off-white solid powder. It has a density of 1.2±0.1 g/cm³, a boiling point of 548.6±50.0°C, and a LogP of 1.04. The compound is soluble in DMSO at ~16.67 mg/mL (~47.57 mM). For in vivo administration, the compound can be formulated in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% saline at ≥1.67 mg/mL. The powder should be stored at -20°C for 3 years and at 4°C for 2 years; in solvent, it is stable at -80°C for 6 months and at -20°C for 1 month. The compound is stable at ambient temperature for a few days during shipping.
|
| Toxicity/Toxicokinetics |
As a natural product, 7beta-Hydroxylathyrol is generally considered safe at low doses. No significant toxicity has been reported in preclinical studies. However, comprehensive toxicological evaluations are needed to establish the compound's safety for potential therapeutic use. The compound is intended for research use only and is not for human use.
|
| Additional Infomation |
7beta-Hydroxylathyrol is a naturally occurring polyoxygenated macrocyclic diterpenoid belonging to the lathyrane class. It is characterized by a 5/11/3-fused-ring skeleton. The compound has a molecular formula of C₂₀H₃₀O₅ and a molecular weight of 350.45. As a natural terpenoid, it has been studied for its potential biological activities, including anti-inflammatory and anti-tumor effects. The compound is structurally related to other bioactive compounds from the Euphorbiaceae family. It is not currently approved for clinical use and is available only for research purposes.
|
| Molecular Formula |
C20H30O5
|
|---|---|
| Molecular Weight |
350.4492
|
| Exact Mass |
350.209
|
| CAS # |
34208-98-5
|
| PubChem CID |
24868376
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
548.6±50.0 °C at 760 mmHg
|
| Flash Point |
299.7±26.6 °C
|
| Vapour Pressure |
0.0±3.3 mmHg at 25°C
|
| Index of Refraction |
1.583
|
| LogP |
1.04
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
25
|
| Complexity |
636
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
C[C@H]1C[C@]2([C@H]([C@H]1O)[C@H](C(=C)[C@@H](C[C@H]3[C@H](C3(C)C)/C=C(\C2=O)/C)O)O)O
|
| InChi Key |
NVDZRSWQWPPKAI-GNQYTXSHSA-N
|
| InChi Code |
InChI=1S/C20H30O5/c1-9-6-12-13(19(12,4)5)7-14(21)11(3)17(23)15-16(22)10(2)8-20(15,25)18(9)24/h6,10,12-17,21-23,25H,3,7-8H2,1-2,4-5H3/b9-6-/t10-,12+,13-,14+,15+,16-,17-,20+/m0/s1
|
| Chemical Name |
(1R,3Z,5R,7S,9R,11R,12R,13S,14S)-1,9,11,13-tetrahydroxy-3,6,6,14-tetramethyl-10-methylidenetricyclo[10.3.0.05,7]pentadec-3-en-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~16.67 mg/mL (~47.57 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.67 mg/mL (4.77 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.67 mg/mL (4.77 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.67 mg/mL (4.77 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8535 mL | 14.2674 mL | 28.5347 mL | |
| 5 mM | 0.5707 mL | 2.8535 mL | 5.7069 mL | |
| 10 mM | 0.2853 mL | 1.4267 mL | 2.8535 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
